# Study of FLOMAX® Versus Placebo in Female Patients With Lower Urinary Tract Symptoms (LUTS) With a Significant Component of Voiding Symptoms

> **NCT02244281** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 74 (actual)

## Conditions studied

- Lower Urinary Tract Symptoms

## Interventions

- **DRUG:** tamsulosin hydrochloride
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02244281
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-05
- **Primary completion:** 2003-11
- **Final completion:** —
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2014-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02244281

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02244281, "Study of FLOMAX® Versus Placebo in Female Patients With Lower Urinary Tract Symptoms (LUTS) With a Significant Component of Voiding Symptoms". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02244281. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*